



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions Pembrolizumab (genetical recombination)

April 20, 2017

## **Non-proprietary name**

Pembrolizumab (genetical recombination)

## **Safety measure**

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be added (underlined parts are revised):

Myocarditis: Myocarditis may occur. Chest pain, increased CK (CPK), electrocardiographic abnormality, etc. should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.